Alnylam Pharmaceuticals, Inc.
Could not find a ticker for this position, may be a filing error
A biopharmaceutical company that makes RNAi therapeutics — medicines that "silence" disease-causing genes — with six marketed drugs including ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO for rare conditions like ATTR amyloidosis. Founded in 2002 by Nobel laureate Phillip Sharp and fellow scientists, its name comes from Alnilam, the bright center star of Orion's belt, chosen as an "aspirational North Star" for genomic medicine. Its ONPATTRO was the first RNAi drug ever approved by the FDA, in 2018.
1.00% Convertible Senior Notes due September 15, 2027
Bought 1.14M
Bought 335.0K · Sold 1.55M
Sold 183.0K
Sold 833.9K
Granted 142.8K · Bought 193.0K · Sold 253.8K
Granted 179.9K · Sold 179.9K
Granted 240.0K · Bought 14.3K · Sold 240.0K
Granted 1.97M · Bought 21.0K · Sold 1.65M
Granted 676.6K · Bought 4.6K · Sold 659.6K
Granted 573.4K · Sold 405.3K
Granted 96.4K · Sold 28.1K
Granted 68.7K · Sold 31.1K
Granted 75.8K · Bought 4.0K · Sold 58.9K
Granted 45.3K · Bought 27.9K · Sold 43.7K
Granted 597.1K · Sold 546.6K
Granted 54.2K · Sold 30.2K
Granted 144.4K · Sold 131.8K
Granted 67.6K · Sold 59.9K
Granted 105.5K · Bought 930 · Sold 80.9K
Granted 14.6K
Sold 3.9K
Granted 50.0K · Sold 50.0K
Granted 8.0K
Granted 211.2K · Bought 11.5K · Sold 210.9K
Granted 138.6K · Sold 150.2K
Granted 11.2K · Sold 7.1K
Granted 185.8K · Sold 178.7K
Granted 1.4K
Granted 60.0K · Bought 1.0K · Sold 60.0K
Granted 1.6K
Granted 19.4K · Bought 36 · Sold 18.0K
Granted 1.4K
Granted 1.4K
Granted 45.0K · Sold 45.0K
Bought 1.0K
Granted 217.6K · Sold 217.6K
Granted 775
Granted 671
Granted 75.1K · Bought 10.0K · Sold 85.0K
Granted 75.0K · Sold 85.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Sanofi10% owner · 5 transactions | — | 10.55Mas of May 2017 | — | 1.14M | — |
| Novartis Ag +1 co-filer10% owner · 4 transactions | — | 4.05Mas of Sep 2012 | — | 335.0K | 1.55M |
| Atlas Venture Associates V LP +7 co-filers10% owner · 16 transactions | — | 1.00Mas of Feb 2006 | — | — | 183.0K |
| Barrett PeterDirector · 54 transactions | — | 503.5Kas of Mar 2006 | — | — | 833.9K |
| Schimmel PaulDirector · 64 transactions | — | 317.0Kas of Mar 2018 | 142.8K | 193.0K | 253.8K |
| Sharp Phillip ADirector · 33 transactions | — | 278.1Kas of Jan 2025 | 179.9K | — | 179.9K |
| Sharp Philip ADirector · 43 transactions | — | 270.1Kas of Apr 2019 | 240.0K | 14.3K | 240.0K |
| Maraganore JohnChief Executive Officer, Director · 409 transactions | — | 231.1Kas of Dec 2021 | 1.97M | 21.0K | 1.65M |
| Greene Barry EPresident · 166 transactions | — | 219.1Kas of Sep 2020 | 676.6K | 4.6K | 659.6K |
| Greenstreet YvonneChief Executive Officer, Director · 240 transactions | — | 98.8K | 573.4K | — | 405.3K |
| Poulton Jeffrey V.EVP, Chief Financial Officer · 153 transactions | — | 63.2K | 96.4K | — | 28.1K |
| Tanguler TolgaEVP, Chief Commercial Officer · 149 transactions | — | 34.3K | 68.7K | — | 31.1K |
| Bonney Michael WDirector · 30 transactions | — | 32.1Kas of Aug 2025 | 75.8K | 4.0K | 58.9K |
| Pyott David E IDirector · 18 transactions | — | 30.0K | 45.3K | 27.9K | 43.7K |
| Vaishnaw AkshayPresident · 212 transactions | — | 26.6Kas of Aug 2023 | 597.1K | — | 546.6K |
| Schulman Amy WDirector · 11 transactions | — | 24.0K | 54.2K | — | 30.2K |
| Garg PushkalEVP Chief R&D · 211 transactions | — | 21.1K | 144.4K | — | 131.8K |
| Fitzgerald Kevin JosephCSO & EVP, Head of Research · 167 transactions | — | 21.1K | 67.6K | — | 59.9K |
| Reid LaurenceSVP, Chief Business Officer · 33 transactions | — | 19.9Kas of Jan 2015 | 105.5K | 930 | 80.9K |
| Supran BryanEVP, CLO and Secretary · 2 transactions | — | 14.6K | 14.6K | — | — |
| McLaughlin MelissaChief Human Resources Officer · 14 transactions | — | 13.4K | — | — | 3.9K |
| Clarke John KDirector · 12 transactions | — | 11.1Kas of May 2018 | 50.0K | — | 50.0K |
| Hesslein Robert W.EVP, CLO and Secretary · 2 transactions | — | 8.0Kas of Mar 2025 | 8.0K | — | — |
| Keating LaurieEVP, Chief Legal Officer · 82 transactions | — | 5.6Kas of Aug 2021 | 211.2K | 11.5K | 210.9K |
| Ausiello Dennis ADirector · 49 transactions | — | 5.1K | 138.6K | — | 150.2K |
| Franchini Indrani LallEVP, CLO & Secretary · 16 transactions | — | 4.1Kas of Feb 2024 | 11.2K | — | 7.1K |
| Mason MichaelVP, Finance and Treasurer · 79 transactions | — | 3.7Kas of Aug 2018 | 185.8K | — | 178.7K |
| Sigal Charles ElliottDirector · 2 transactions | — | 3.4K | 1.4K | — | — |
| Paul Steven MDirector · 16 transactions | — | 3.3Kas of Apr 2022 | 60.0K | 1.0K | 60.0K |
| Hamburg Margaret ADirector · 3 transactions | — | 1.6K | 1.6K | — | — |
| Reitan Colleen FDirector · 22 transactions | — | 1.4K | 19.4K | 36 | 18.0K |
| Brandicourt OlivierDirector · 2 transactions | — | 1.4K | 1.4K | — | — |
| Kellogg Peter NDirector · 2 transactions | — | 1.4K | 1.4K | — | — |
| Allen Patricia LVP of Finance/Treasurer · 54 transactions | — | 1.2Kas of Dec 2010 | 45.0K | — | 45.0K |
| Gros David-Alexandre CSVP, Chief Business Officer · 2 transactions | — | 1.0Kas of Feb 2016 | — | 1.0K | — |
| Starr Kevin PDirector · 29 transactions | — | 900as of Nov 2015 | 217.6K | — | 217.6K |
| Bertozzi Carolyn RDirector · 1 transaction | — | 775as of May 2025 | 775 | — | — |
| Arbuckle Stuart ADirector · 1 transaction | — | 671 | 671 | — | — |
| Fanucci MarshaDirector · 11 transactions | — | 136as of Feb 2023 | 75.1K | 10.0K | 85.0K |
| Soni Manmeet SinghChief Financial Officer · 5 transactions | — | 83as of Jul 2018 | — | — | — |
| Vincent James LDirector · 14 transactions | — | 0as of Jun 2010 | 75.0K | — | 85.0K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -6.32M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.